Technology & Science
Four connected layers. One more personal experience.
NeuroLounge brings together established external technologies with Thaléa's own developing experience and intelligence layers.
The architecture
Clear about what exists — and what we are building.
Two layers are independent external technologies. Two are being developed by Thaléa. Together they form the proposed NeuroLounge experience.
Hardware
Programmable TMS hardware
Proposed programmable TMS equipment from an established external manufacturer — the hardware responsible for delivering magnetic stimulation.
External technologyMethodology
EEG-informed personalized neuromodulation
An externally developed, EEG-informed individualized rTMS methodology intended to inform participant-specific stimulation parameters, subject to qualified clinical oversight.
External technologyExperience
Thaléa / NeuroLounge
The integrated participant journey, premium physical environment, personal intentions, experience design and follow-through.
Thaléa — in developmentIntelligence & orchestration
The Thaléa System
A developing framework intended to connect individual intentions, relevant context, experiences, responses, memory and meaningful progression over time.
Thaléa — in developmentThe hardware and methodology layers are developed by independent external providers and are referenced as proposed components. Thaléa does not own these technologies, and no endorsement, partnership, licensing or supply agreement is implied.
Scientific foundation
Three distinct levels of evidence.
Established
rTMS research
Repetitive transcranial magnetic stimulation has an established clinical research foundation for specific studied indications and protocols, including randomized controlled trials in major depression. These findings do not extend to general cognitive enhancement or wellness outcomes.
Emerging
EEG-informed personalized rTMS research
EEG-informed personalized approaches have an emerging research foundation. Published findings should be read separately from broader hypotheses, and conventional rTMS findings do not by themselves establish the efficacy of any specific personalized methodology.
Not yet validated
Integrated NeuroLounge
The complete integrated NeuroLounge experience has not yet established product-specific clinical outcomes or validated commercial operating performance.
Selected scientific references — established rTMS
- O'Reardon JP, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biological Psychiatry, 2007. Read publication
- Blumberger DM, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. The Lancet, 2018. Read publication
Technology roles and boundaries
Measurement, methodology and delivery are different responsibilities.
Programmable TMS hardware
TMS hardware delivers magnetic pulses through a stimulation coil. In the proposed NeuroLounge configuration, the hardware is the delivery platform; it does not itself define the participant's intentions, establish clinical suitability or provide the wider Thaléa experience.
The exact equipment configuration, permitted uses, accessories, installation requirements and supplier arrangements must be confirmed for each deployment. No specific device clearance, licensing agreement or completed Thaléa installation is asserted here.
EEG-informed personalization
The proposed personalized rTMS methodology uses EEG information to inform individualized stimulation parameters, rather than treating every participant's neurological characteristics as interchangeable. EEG acquisition, interpretation, proposed parameters and clinical authorization are separate steps. EEG records electrical activity at the scalp; it does not independently diagnose a condition or guarantee treatment response. No real-time monitoring, continuous brain tracking or automatic treatment adaptation is claimed.
Individualization does not remove the need for screening, qualified clinical judgment or an authorized delivery model. The specific protocol, methodology access and evidence relevant to a proposed population require verification; the method is not interchangeable with every studied conventional rTMS protocol.
NeuroLounge integrates these proposed external components with the participant journey. The developing Thaléa System concerns future continuity across experiences, not a prerequisite for personalized neuromodulation delivery. Neither the integrated NeuroLounge experience nor the System is validated by the existence of the hardware or methodology alone.
Regulatory and clinical responsibility
Responsible delivery comes first.
Clinical delivery requires appropriate equipment, authorized use, qualified personnel, clinical oversight, insurance, informed consent, data protection and jurisdiction-specific compliance.
Device certification alone does not authorize every proposed wellness application. Each deployment's regulatory pathway is assessed individually.
Layer 4
Beyond the session: the Thaléa System.
The intelligence and orchestration layer — its intended architecture, connections across an operator's services and longer-term value.
Partnership
Explore what NeuroLounge could mean for your property.
Begin with a strategic conversation about your environment, guests and ambitions.
Explore a Partnership